These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 17368185

  • 1. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
    Brown AJ.
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
    [Abstract] [Full Text] [Related]

  • 2. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Nov; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 5. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.
    Brown AJ, Coyne DW.
    Treat Endocrinol; 2002 Nov; 1(5):313-27. PubMed ID: 15832485
    [Abstract] [Full Text] [Related]

  • 6. Vitamin D analogs: perspectives for treatment.
    Brown AJ, Slatopolsky E.
    Miner Electrolyte Metab; 1999 Nov; 25(4-6):337-41. PubMed ID: 10681662
    [Abstract] [Full Text] [Related]

  • 7. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
    Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G.
    J Nephrol; 2006 Nov; 19(5):566-77. PubMed ID: 17136683
    [Abstract] [Full Text] [Related]

  • 8. Vitamin D analogues for the management of secondary hyperparathyroidism.
    Martin KJ, González EA.
    Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
    [Abstract] [Full Text] [Related]

  • 9. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ, Shaheen FA.
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [Abstract] [Full Text] [Related]

  • 10. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A.
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [Abstract] [Full Text] [Related]

  • 11. [Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism].
    Tanaka H, Komaba H, Fukagawa M.
    Clin Calcium; 2011 Nov; 21(11):27-34. PubMed ID: 22040818
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D analogues for secondary hyperparathyroidism.
    Brown AJ, Dusso AS, Slatopolsky E.
    Nephrol Dial Transplant; 2002 Nov; 17 Suppl 10():10-9. PubMed ID: 12386264
    [Abstract] [Full Text] [Related]

  • 13. Bone health and vascular calcification relationships in chronic kidney disease.
    Spasovski GB.
    Int Urol Nephrol; 2007 Nov; 39(4):1209-16. PubMed ID: 17899431
    [Abstract] [Full Text] [Related]

  • 14. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A.
    Semin Dial; 2005 Nov; 18(3):226-38. PubMed ID: 15934970
    [Abstract] [Full Text] [Related]

  • 15. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
    Slatopolsky E, Finch JL, Brown AJ, Ritter CS, Mizobuchi M, Plum LA, Clagett-Dame M, Sicinski RR, DeLuca HF.
    J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
    [Abstract] [Full Text] [Related]

  • 16. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells.
    Brown AJ, Ritter CS, Knutson JC, Strugnell SA.
    Nephrol Dial Transplant; 2006 Mar; 21(3):644-50. PubMed ID: 16221703
    [Abstract] [Full Text] [Related]

  • 17. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
    Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J, ADVANCE Study Group.
    Nephrol Dial Transplant; 2011 Apr; 26(4):1327-39. PubMed ID: 21148030
    [Abstract] [Full Text] [Related]

  • 18. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR, Tian J, Goltzman D.
    Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
    [Abstract] [Full Text] [Related]

  • 19. New vitamin D analogs.
    Slatopolsky E, Finch J, Brown A.
    Kidney Int Suppl; 2003 Jun; (85):S83-7. PubMed ID: 12753273
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.